Evidence map›Paper›PMID 31086268›Full record

ArticleScientific reports2019

5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl)methyl]-L-proline Inhibits Hepatitis C Virus Entry.

Lap P Nguyen, Chorong Park, Trang T D Luong, Eun-Mee Park, Dong-Hwa Choi, Kang Min Han, Han N Mai, Huu C Nguyen, Yun-Sook Lim, Soon B Hwang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Lap P NguyenLaboratory of RNA Viral Diseases, Korea Zoonosis Research Institute, Chonbuk National University, Iksan, South Korea.
Chorong ParkNational Research Laboratory of Hepatitis C Virus, Hallym University, Anyang, South Korea.
Trang T D LuongNational Research Laboratory of Hepatitis C Virus, Hallym University, Anyang, South Korea.
Eun-Mee ParkKorea National Institute of Health, Cheongju, South Korea.
Dong-Hwa ChoiGraduate School of East-West Medical Science, Kyung Hee University, Yongin, South Korea.
Kang Min HanDepartment of Pathology, Dongguk University Ilsan Hospital, Goyang, South Korea.
Han N MaiLaboratory of RNA Viral Diseases, Korea Zoonosis Research Institute, Chonbuk National University, Iksan, South Korea.
Huu C NguyenLaboratory of RNA Viral Diseases, Korea Zoonosis Research Institute, Chonbuk National University, Iksan, South Korea.
Yun-Sook LimLaboratory of RNA Viral Diseases, Korea Zoonosis Research Institute, Chonbuk National University, Iksan, South Korea. yunsolim@hanmail.net.
Soon B HwangLaboratory of RNA Viral Diseases, Korea Zoonosis Research Institute, Chonbuk National University, Iksan, South Korea. sbhwang@jbnu.ac.kr.
Hallym University · KRDongguk University Ilsan Hospital · KRJeonbuk National University · KRKorea National Institute of Health · KRKyung Hee University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus (HCV) is the major causative agent of chronic liver diseases, including liver cirrhosis and hepatocellular carcinoma. The recent development of highly effective direct-acting antivirals (DAAs) has revolutionized the treatment of HCV patients. However, these DAAs are exorbitantly expensive for the majority of HCV patients worldwide. Moreover, these drugs still show genotypic difference in cure rate and have some resistant-associated variants. Tylophorine, a natural compound derived from Tylophora indica plants, is known to have anti-inflammatory and anti-cancerous growth activities. In the present study, we showed that two tylophorine intermediates, 5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl) methyl]-L-proline (O859585) and 2,3,6,7-tetramethoxy-9-phenanthrenecarboxylic acid (T298875), displayed anti-HCV activity with an EC

Indexed as

AlkaloidsAntiviral AgentsCell Line, TumorCell SurvivalDrug SynergismDrug Therapy, CombinationHEK293 CellsHepacivirusHepatitis C, ChronicHepatocytesHumansIndolizinesInterferon-alphaPhenanthrenesPrimary Cell CultureProlineAlkaloidsAntiviral AgentsCD81 protein, humanglycoprotein E2, Hepatitis C virusIndolizinesInterferon-alphaPhenanthrenesProlineSofosbuvirTetraspanin 28tylophorineViral Envelope Proteins

Identifiers

PMID31086268
PMCPMC6514212
OpenAlexW2944734970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.